Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
Authors:
- Rakesh KumarRKRakesh Kumar
- Stephen J BlakemoreSBStephen J Blakemore
- Catherine E EllisCECatherine E Ellis
- Emanuel F PetricoinEPEmanuel F Petricoin
- Dexter PrattDPDexter Pratt
- Michael MacorittoMMMichael Macoritto
- Andrea L MatthewsAMAndrea L Matthews
- Joseph J LoureiroJLJoseph J Loureiro
- Keith EllistonKEKeith Elliston
Open Access
- 6 July 2010
- journal article
- Published by Springer Nature in BMC Genomics
- Vol. 11 (1) , 419
Abstract
Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A novel, pan AKT kinase inhibitor, GSK690693, was developed in order to interfere with the inappropriate AKT signaling seen in these human malignancies. Causal network modeling is a systematic computational analysis that identifies upstream changes in gene regulation that can serve as explanations for observed changes in gene expression. In this study, causal network modeling is employed to elucidate mechanisms of action of GSK690693 that contribute to its observed biological effects. The mechanism of action of GSK690693 was evaluated in multiple human tumor cell lines from different tissues in 2-D cultures and xenografts using RNA expression and phosphoproteomics data. Understanding the molecular mechanism of action of novel targeted agents can enhance our understanding of various biological processes regulated by the intended target and facilitate their clinical development.Keywords
This publication has 42 references indexed in Scilit:
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathwayCellular Signalling, 2006
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- The Akt/PKB pathway: molecular target for cancer drug discoveryOncogene, 2005
- Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting2005
- Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancerNature Medicine, 2002
- PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrestNature Medicine, 2002
- PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer modelHuman Molecular Genetics, 2001
- Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors.2000